Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06147960
Other study ID # NIMAO/2023-1/FF-01
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 2023
Est. completion date November 2024

Study information

Verified date November 2023
Source Centre Hospitalier Universitaire de Nimes
Contact Frédéric FITENI, Dr.
Phone +334.34.03.46.69
Email frederic.fiteni@chu-nimes.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.


Description:

Cervical cancer remains one of the most common cancers in women in terms of both incidence and mortality. Human Papilloma Virus carriage is a necessary condition for the development of these cancers but is not the only factor responsible for malignant transformation. Numerous molecular alterations come into play in the development of these tumours, involving the activation of oncogenes or the inactivation of tumour suppressor genes. Treatment of locally-advanced cancer is based on radiotherapy or a combination of radiotherapy and chemotherapy. Responses to anti-neoplastic treatments remain very heterogeneous from one woman to another. Predicting the response to these treatments would make it possible to envisage early therapeutic alternatives for patients identified as not very sensitive to standard treatments. IAPs (inhibitors of apoptosis proteins), which include XIAP, cIAP1 and cIAP2, are proteins involved in many cancers and capable of downregulating tumour cell apoptosis. It seems justified to investigate the role of these IAPs in resisting apoptosis-inducing anti-neoplastic treatments such as chemotherapy or radiotherapy. The aim of our study is to assess the prognostic role of overexpression of IAPs in locally advanced cervical cancer treated exclusively with radio-chemotherapy. This research seems all the more important as IAP-inhibiting molecules are currently being studied in other types of cancer (ear, nose and throat cancers) and appear to have a very encouraging radiosensitising effect. The hypothesis is that overexpression of IAPs in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy has a prognostic role on the local recurrence rate at 24 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date November 2024
Est. primary completion date May 2024
Accepts healthy volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification). - Patients aged = 18 years. - Patients with a minimum of 2 years post-treatment follow-up. - Patients for whom the initial biopsy specimen (before treatment) is available. - Patients who have not indicated that they do not wish to participate in the study. - Patients affiliated to or benefiting from a health insurance scheme. Exclusion Criteria: - Patients under court protection, guardianship or curatorship.

Study Design


Intervention

Diagnostic Test:
Immunohistochemistry
Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes Institut du Cancer de Montpellier - Val d'Aurelle

Outcome

Type Measure Description Time frame Safety issue
Other Age Age will be recorded in years Baseline
Other Weight Weight will be recorded in kilograms Baseline
Other Height Height will be recorded in centimeters Baseline
Other Radiotherapy protocol The patient's radiotherapy protocol will be recorded Baseline
Other Chemotherapy Details of the patient's chemotherapy will be recorded (drugs and dosage) Baseline
Other Brachytherapy Details of the patient's brachytherapy will be recorded (type of internal radiation and dosage) Baseline
Other Anatomopathology of cervical cancer: histology The histology of the patient's cervical cancer will be recorded Baseline
Other Anatomopathology of cervical cancer: FIGO stage The FIGO stage of the patient's cervical cancer will be recorded. FIGO staging ranges from Stage I= Confined to the uterine corpus and ovary to Stage IIB=Substantial lymphovascular space involvement of non-aggressive histological types. Baseline
Other Family and personal history The patient's family and personal history will be recorded Baseline
Other Co-medications Any other concommitant treatment will be recorded Baseline
Other Initial clinical features The initial clinical features of the disease will be recorded Baseline
Other Lifestyle The patient's lifestyle (marital status, children, hobbies, professional status) will be recorded Baseline
Other Follow-up All details of follow-up of the patient's oncological pathology (response rate, date of progression, date of death) will be recorded. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Other Treatments received after progression Details of all treatments received after disease progression will be recorded From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Primary Prognostic role of overexpression of XIAP on the rate of local recurrence in patients treated for locally advanced cervical cancer. Overexpression of the Inhibitor of Apoptosis Proteins XIAP will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. The H-score for XIAP will be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. Baseline
Primary Prognostic role of overexpression of XIAP on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. Overexpression of the Inhibitor of Apoptosis Proteins XIAP will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. The H-score for XIAP will be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. 24 months
Primary Prognostic role of overexpression of cIAP1 on the rate of local recurrence in patients treated for locally advanced cervical cancer. Overexpression of Inhibitors of the Apoptosis Protein cIAP1 will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer.The H-score for cIAP1 be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. Baseline
Primary Prognostic role of overexpression of cIAP1 on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. Overexpression of the Inhibitor of Apoptosis Protein cIAP1 will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer.The H-score for cIAP1 be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. 24 months
Primary Prognostic role of overexpression of cIAP2 on the rate of local recurrence in patients treated for locally advanced cervical cancer. Overexpression of the Inhibitor of Apoptosis Protein cIAP2 will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer.The H-score for cIAP2 be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. Baseline
Primary Prognostic role of overexpression of cIAP2 on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. Overexpression of the Inhibitor of Apoptosis Protein cIAP2 will be measured to evaluate its prognostic role on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer. The H-score for cIAP1 be recorded on a scale of 0 to 300 based on the intensity of carcinoma cells. 24 months
Primary Local recurrence of cervical cancer Local recurrence of cervical cancer at 24 months follow-up according to RECIST v1.1 criteria: Yes/No.
RECIST 1.1 is a standard way to measure the response of a tumor to treatment in which Complete Response = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. Partial Response = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Overall survival at 24 months follow-up in patients treated for locally advanced cervical cancer.
Secondary A. Overall survival in patients treated for locally advanced cervical cancer at baseline. Death will be recorded as YES/NO Baseline
Secondary A. Overall survival at 24 months follow-up in patients treated for locally advanced cervical cancer. Death will be recorded as YES/NO 24 months
Secondary B. Progression-free survival in patients treated for locally advanced cervical cancer. The time from diagnosis to death from any cause will be recorded in months and days. Baseline
Secondary B. Progression-free survival at 24 months follow-up in patients treated for locally advanced cervical cancer. The time from diagnosis to death from any cause will be recorded in months and days. 24 months
Secondary B. Progression-free survival in patients treated for locally advanced cervical cancer: RECIST criteria The time between diagnosis and progression according to v1.1 of the RECIST criteria or death from any cause will be recorded in days.
RECIST 1.1 is a standard way to measure the response of a tumor to treatment in which Complete Response = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. Partial Response = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Baseline
Secondary B. Progression-free survival at 24 months follow-up in patients treated for locally advanced cervical cancer: RECIST criteria The time between diagnosis and progression according to v1.1 of the RECIST criteria or death from any cause will be recorded in days.
RECIST 1.1 is a standard way to measure the response of a tumor to treatment in which Complete Response = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. Partial Response = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
24 months
Secondary B. Progression-free survival in patients treated for locally advanced cervical cancer. H-score The histochemical scoring assessment (H-SCORE) will be recorded on a scale of 0-300 Baseline
Secondary B. Progression-free survival at 24 months follow-up in patients treated for locally advanced cervical cancer: H-score The histochemical scoring assessment (H-SCORE) will be recorded on a scale of 0-300 24 months
Secondary C. Correlation between the Inhibitor of Apoptosis Protein XIAP expression and Programmed Death - Ligand 1 expression. The expression level of XIAP and the expression level of PD-L1 in biopsies will be measured by immunohistochemistry. Baseline
Secondary C. Correlation between the Inhibitor of Apoptosis Protein cIAP1 expression and Programmed Death - Ligand 1 expression. The expression level of cIAP1 and the expression level of PD-L1 in biopsies will be measured by immunohistochemistry. Baseline
Secondary C. Correlation between the Inhibitor of Apoptosis Protein cIAP2 expression and Programmed Death - Ligand 1 expression. The expression levels of cIAP2 and expression level of PD-L1 in biopsies will be measured by immunohistochemistry. Baseline
Secondary D. Correlation between the Inhibitor of Apoptosis Protein XIAP expression and lymphocytic tumour infiltration (LTI). The expression level of XIAP and the level of lymphocytic tumour infiltration will be measured as % in biopsies. Baseline
Secondary D. Correlation between the Inhibitor of Apoptosis Protein cIAP1 expression and lymphocytic tumour infiltration (LTI). The expression level of cIAP1 and the level of lymphocytic tumour infiltration will be measured as % in biopsies. Baseline
Secondary D. Correlation between the Inhibitor of Apoptosis Protein cIAP2 expression and lymphocytic tumour infiltration (LTI). The expression level of cIAP2 and the level of lymphocytic tumour infiltration will be measured as % in biopsies. Baseline
See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT00193739 - Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix Phase 3
Not yet recruiting NCT04999696 - Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer N/A
Completed NCT02309658 - Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Phase 2
Completed NCT00193752 - Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix N/A
Recruiting NCT00154479 - The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus N/A
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Completed NCT05149248 - Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Phase 2/Phase 3
Completed NCT00191100 - Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Phase 3
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Recruiting NCT05742711 - Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients N/A
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Active, not recruiting NCT05709730 - Follow-up of Cell Changes in the Cervix
Completed NCT00193791 - Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix N/A
Withdrawn NCT02312804 - Ph Ib/BGJ398/Cervix and Other Solid Tumors Phase 1
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Completed NCT00193804 - A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix
Completed NCT04809727 - Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy N/A